Novavax plans to make at least 2 billion doses of COVID-19 vaccine available in 2022

September 10 (Reuters) – Vaccine developer Novavax Inc (NVAX.O) said on Friday that at least 2 billion doses of its COVID-19 vaccine would be available in 2022.

The company, which announced in June that its vaccine was over 90% effective in an advanced stage clinical trial based in the United States, said it was on track to file an application for the use of emergency of his vaccine with the United States Food and Drug Administration in the fourth quarter.

Novavax, speaking at a Morgan Stanley healthcare conference, reiterated that it will have around 100 million doses per month by the end of the third quarter of this year, and will increase it to 150 million doses in the fourth quarter.

“We are already engaged in conversations about additional purchases for the second half of 2022, as well as early in 2023, especially given current vaccination rates around the world,” said John Trizzino, Commercial Director of Novavax , adding that the recall strategy would create additional demand for its vaccines.

In recent months, Novavax has entered into several supply agreements around the world for its protein-based vaccine, including an agreement with the European Commission for 200 million doses.

Report by Dania Nadeem and Mrinalika Roy in Bengaluru; Editing by Amy Caren Daniel

Our Standards: The Thomson Reuters Trust Principles.